Investor List:

Top Drug Delivery Series A Investors in New York City (5)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Drug Delivery investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of George C. Petrocheilos, Managing Partner at Catalio Capital
George C. Petrocheilos
Catalio Capital·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Baltimore (MD), Investors in Athens (Greece), Investors in New York (NY)
Investors in Medical Devices (Seed), Investors in Robotics (Seed), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Robotics (Series B), Investors in Robotics (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Medical Devices (Seed), Investors in Medical Devices (Seed), Investors in Robotics (Seed), Investors in Robotics (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in Robotics (Series A), Investors in Medical Devices (Series A), Investors in BioTech (Series B), Investors in Robotics (Series A), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Robotics (Series B), Investors in Medical Devices (Series B), Investors in Robotics (Series B), Investors in Washington, D.C. (Other Lists), Investors in Cybersecurity (Seed), Investors in Diagnostics (Series A), Investors in Drug Delivery (Series A), Investors in Diagnostics (Seed), Investors in Cybersecurity (Series A), Investors in Cybersecurity (Series B), Investors in Cybersecurity (Series B), Investors in Cybersecurity (Series A), Investors in Diagnostics (Series B), Investors in Cybersecurity (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Cybersecurity (Series A), Investors in Cybersecurity (Seed), Investors in Cybersecurity (Series B), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed)
Photo of Claes Wahlestedt, PhD, MD, Vice President at Pacific Biosciences
Claes Wahlestedt, PhD, MD
Pacific Biosciences·Vice President
Sweet spot: $10.0M
Range: $1M - $20.0M
Investors in Boston (MA), Investors in San Diego (CA), Investors in New York (NY), Investors in SF Bay Area (CA), Investors in San Francisco (CA)
Investors in Drug Delivery (Series A), Investors in Drug Delivery (Pre-seed), Investors in Consumer Health (Series A), Investors in Consumer Health (Pre-seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health IT (Pre-seed), Investors in AI (Series A), Investors in AI (Seed), Investors in AI (Pre-seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Pre-seed), Investors in Los Angeles / Southern California (Other Lists), Investors in Consumer Health (Seed), Investors in Pharmaceuticals (Series B), Investors in AI (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Digital Health (Series A), Investors in BioTech (Seed), Investors in AI (Series B), Investors in Diagnostics (Seed), Investors in AI (Pre-seed), Investors in Consumer Health (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health IT (Series B), Investors in Drug Delivery (Series A), Investors in Consumer Health (Seed), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Pre-seed), Investors in Generative Tech/AI (Series A), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Pre-seed), Investors in AI (Seed), Investors in Consumer Health (Seed), Investors in AI (Series A), Investors in Digital Health (Seed), Investors in Generative Tech/AI (Pre-seed), Investors in AI (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series B), Investors in Digital Health (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health IT (Seed), Investors in Diagnostics (Series B), Investors in Drug Delivery (Series A), Investors in AI (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Consumer Health (Series B), Investors in Diagnostics (Series A), Investors in Drug Delivery (Seed), Investors in Pharmaceuticals (Seed), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Pre-seed), Investors in Pharmaceuticals (Seed), Investors in Drug Delivery (Series B), Investors in Pharmaceuticals (Seed), Investors in Health IT (Seed), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series B), Investors in Digital Health (Series A), Investors in Health IT (Seed), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series B), Investors in Generative Tech/AI (Series B), Investors in BioTech (Series A), Investors in Consumer Health (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in AI (Series A), Investors in Drug Delivery (Pre-seed), Investors in Generative Tech/AI (Series A), Investors in Consumer Health (Series A), Investors in San Francisco Bay Area (Other Lists), Investors in Diagnostics (Series B), Investors in BioTech (Series A), Investors in Consumer Health (Series B), Investors in Digital Health (Pre-seed), Investors in Consumer Health (Series A), Investors in Digital Health (Seed), Investors in Health IT (Pre-seed), Investors in Drug Delivery (Pre-seed), Investors in Health & Hospital Services (Seed), Investors in Health & Hospital Services (Series B), Investors in AI (Series A), Investors in Health IT (Series A), Investors in BioTech (Pre-seed), Investors in Generative Tech/AI (Seed), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series A), Investors in BioTech (Series B), Investors in Consumer Health (Pre-seed), Investors in Health & Hospital Services (Series A), Investors in Consumer Health (Series B), Investors in Health & Hospital Services (Series A), Investors in Consumer Health (Series B), Investors in BioTech (Pre-seed), Investors in AI (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series A), Investors in Diagnostics (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Pre-seed), Investors in Generative Tech/AI (Seed), Investors in AI (Series B), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series A), Investors in Pharmaceuticals (Pre-seed), Investors in Health IT (Series B), Investors in Diagnostics (Seed), Investors in Consumer Health (Pre-seed), Investors in Pharmaceuticals (Series B), Investors in Drug Delivery (Series B), Investors in Generative Tech/AI (Seed), Investors in Pharmaceuticals (Series B), Investors in Diagnostics (Series B), Investors in Digital Health (Series A), Investors in Diagnostics (Pre-seed), Investors in Boston / New England (Other Lists), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Pre-seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Digital Health (Series B), Investors in Diagnostics (Seed), Investors in Digital Health (Series B), Investors in AI (Series B), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series B), Investors in Generative Tech/AI (Series B), Investors in Drug Delivery (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series B), Investors in Drug Delivery (Seed), Investors in Diverse Investors (Other Lists), Investors in Digital Health (Series A), Investors in Drug Delivery (Series B), Investors in Health IT (Pre-seed), Investors in AI (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Generative Tech/AI (Series B), Investors in Pharmaceuticals (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Consumer Health (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Generative Tech/AI (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Generative Tech/AI (Seed), Investors in Digital Health (Pre-seed), Investors in Generative Tech/AI (Pre-seed), Investors in Generative Tech/AI (Pre-seed), Investors in Generative Tech/AI (Series A), Investors in Generative Tech/AI (Series A), Investors in Generative Tech/AI (Series B), Investors in Drug Delivery (Pre-seed), Investors in Drug Delivery (Series A), Investors in New York City (Other Lists), Investors in Pharmaceuticals (Seed), Investors in Investors who invested in diverse founders (Other Lists), Investors in Diagnostics (Seed), Investors in Investors who were founders (Other Lists), Investors in Health & Hospital Services (Seed), Investors in AI (Seed), Investors in Digital Health (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in AI (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Consumer Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health IT (Pre-seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Pre-seed), Investors in Generative Tech/AI (Pre-seed), Investors in Generative Tech/AI (Seed), Investors in Consumer Health (Seed), Investors in Health IT (Seed), Investors in Consumer Health (Series B), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series A), Investors in Investors who invested in female founders (Other Lists), Investors in BioTech (Series B), Investors in AI (Series B), Investors in AI (Series A), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Generative Tech/AI (Series A), Investors in Generative Tech/AI (Series B), Investors in Consumer Health (Series A)
Photo of Jonathan Soll, Analyst at New Rhein Healthcare Investors
Jonathan Soll
Sweet spot: $25.0M
Range: $20.0M - $50.0M
Investors in Philadelphia (PA)
Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Consumer Health (Series A), Investors in Medical Devices (Series A), Investors in Diverse Investors (Other Lists), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in Consumer Health (Seed), Investors in BioTech (Seed), Investors in Consumer Health (Seed), Investors in BioTech (Series A), Investors in New York City (Other Lists), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Consumer Health (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series A), Investors in Diagnostics (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed)
Photo of Shannon Bergstedt, Principal at Foresite Capital
Shannon Bergstedt
Foresite Capital·Principal
Sweet spot: $38.5M
Range: $2.0M - $75.0M
Investors in New York (NY)
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series B), Investors in Medical Devices (Seed), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in Medical Devices (Series A), Investors in New York City (Other Lists), Investors in BioTech (Seed), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Drug Delivery (Series A), Investors in Therapeutics (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Therapeutics (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Seed), Investors in Digital Health (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Health IT (Series B), Investors in Health IT (Seed)
Photo of Alexander Shilman, Managing Partner at New Gate Capital
Alexander Shilman
New Gate Capital·Managing Partner
Sweet spot: $2.0M
Range: $150K - $5.0M
Investors in London, Investors in New York (NY), Investors in Jerusalem (Israel), Investors in Tel Aviv-Yafo (Israel)
Investors in Robotics (Seed), Investors in IoT (Seed), Investors in Robotics (Seed), Investors in Robotics (Seed), Investors in Food and Beverage (Series A), Investors in DeepTech (Seed), Investors in Israel (Other Lists), Investors in IoT (Seed), Investors in IoT (Seed), Investors in ClimateTech/CleanTech (Series A), Investors in ClimateTech/CleanTech (Series A), Investors in IoT (Series A), Investors in DeepTech (Seed), Investors in DeepTech (Series A), Investors in ClimateTech/CleanTech (Series A), Investors in AI (Seed), Investors in IoT (Seed), Investors in Robotics (Series A), Investors in Smart Cities/UrbanTech (Series A), Investors in Food and Beverage (Series A), Investors in New York City (Other Lists), Investors in Drug Delivery (Series A), Investors in EnergyTech (Series A), Investors in ClimateTech/CleanTech (Seed), Investors in Robotics (Series A), Investors in IoT (Series A), Investors in AI (Series A), Investors in Diverse Investors (Other Lists), Investors in ClimateTech/CleanTech (Seed), Investors in Robotics (Seed), Investors in AI (Series A), Investors in IoT (Series A), Investors in Robotics (Series A), Investors in Robotics (Series A), Investors in DeepTech (Seed), Investors in Smart Cities/UrbanTech (Seed), Investors in AI (Seed), Investors in Investors who were founders (Other Lists), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in ClimateTech/CleanTech (Seed), Investors in Food and Beverage (Seed), Investors in Food and Beverage (Seed), Investors in Food and Beverage (Series A), Investors in Food and Beverage (Series A), Investors in London (Other Lists), Investors in Drug Delivery (Series A), Investors in Smart Cities/UrbanTech (Series A), Investors in EnergyTech (Seed), Investors in AI (Seed), Investors in ClimateTech/CleanTech (Seed), Investors in Food and Beverage (Seed), Investors in EnergyTech (Series A), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Seed), Investors in DeepTech (Series A), Investors in Smart Cities/UrbanTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in AI (Seed), Investors in EnergyTech (Seed), Investors in EnergyTech (Seed), Investors in AI (Series A), Investors in AI (Series A), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in ClimateTech/CleanTech (Series A), Investors in BioTech (Series A), Investors in EnergyTech (Series A), Investors in EnergyTech (Series A), Investors in IoT (Series A), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Seed), Investors in DeepTech (Seed), Investors in DeepTech (Series A), Investors in DeepTech (Series A), Investors in Smart Cities/UrbanTech (Seed), Investors in Smart Cities/UrbanTech (Series A), Investors in Smart Cities/UrbanTech (Seed), Investors in Smart Cities/UrbanTech (Seed), Investors in EnergyTech (Seed), Investors in Food and Beverage (Seed), Investors in BioTech (Series A)
Get new data & insights delivered to your inbox